You are here: Industry Insights > gilead

News List

Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy pharmatimes
March 08, 2021
Gilead Sciences has revealed new, four-year data from two Phase III studies evaluating Biktarvy for the treatment of HIV-1 in treatment-naïve adults.
Gilead 4Q Revenues up 26% contractpharma
February 10, 2021
Revenue growth for the quarter and full year was primarily due to the launch of Veklury (remdesivir).
Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B prnasia
February 04, 2021
Gilead Sciences announced today at the 2021 Asian Pacific Association for the Study of the Liver Conference (APASL), findings from two sub-analyses that demonstrated the continued efficacy and improved safety of Vemlidy® ...
Gilead, Gritstone Enter Vax Platform Pact for HIV Cure contractpharma
February 02, 2021
Aims to develop HIV-specific vaccine using Gritstone’s prime-boost vaccine platform with antigens developed by Gilead.
Gilead's Veklury should be effective against COVID-19 variants pharmatimes
January 25, 2021
Gilead Sciences has released a statement regarding the efficacy of its antiviral treatment Veklury (remdesivir), maintaining confidence in the its continued benefit against new COVID-19 variants.
Gilead and Vir unite to find a ‘functional cure’ for hepatitis B pharmatimes
January 15, 2021
Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a ‘functional cure’ for chronic hepatitis B virus (HBV).
Gilead's CAR T therapy Tecartus authorised in EU for MCL pharmatimes
December 18, 2020
Gilead’s Kite division has announced that its chimericantigen receptor (CAR) T cell therapy Tecartus has received conditional marketing authorisation for the treatment of relapsed or refractory mantle cell lymphoma (MCL).
Gilead, Galapagos amend commercialisation and development pact for Jyseleca (filgotinib) expresspharma
December 16, 2020
Under the new arrangement, Galapagos will assume sole responsibility in Europe for filgotinib in RA, Gilead to receive royalties on European sales starting in 2024.
Gilead’s CAR T therapy Yescarta shows potential in new indication pharmatimes
December 10, 2020
Gilead’s Yescarta has scored some promising interim results from a phase II study evaluating the chimeric antigen receptor (CAR) T therapy as a first-line treatment for high-risk large B-cell lymphoma (LBCL) patients.
WHO takes off remdesivir from prequalification list of medicines for COVID-19 expresspharma
November 23, 2020
It is an official list of medicines used as a benchmark for procurement by developing countries.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page